Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recognition of and treatment recommendations for oligometastatic disease in multidisciplinary tumor boards.
Christ SM, Heesen P, Muehlematter UJ, Pohl K, William Thiel G, Willmann J, Ahmadsei M, Kroese TE, Mayinger M, Balermpas P, Wicki A, Andratschke N, Huellner M, Guckenberger M. Christ SM, et al. Among authors: andratschke n. Clin Transl Radiat Oncol. 2022 Nov 15;38:123-129. doi: 10.1016/j.ctro.2022.11.008. eCollection 2023 Jan. Clin Transl Radiat Oncol. 2022. PMID: 36420098 Free PMC article.
Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M, Klement RJ, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N, Flentje M. Guckenberger M, et al. Among authors: andratschke n. Radiother Oncol. 2013 Oct;109(1):13-20. doi: 10.1016/j.radonc.2013.09.005. Epub 2013 Oct 30. Radiother Oncol. 2013. PMID: 24183066
Support vector machine-based prediction of local tumor control after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
Klement RJ, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N, Guckenberger M. Klement RJ, et al. Among authors: andratschke n. Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):732-8. doi: 10.1016/j.ijrobp.2013.11.216. Epub 2014 Jan 7. Int J Radiat Oncol Biol Phys. 2014. PMID: 24411630
SBRT in operable early stage lung cancer patients.
Roesch J, Andratschke N, Guckenberger M. Roesch J, et al. Among authors: andratschke n. Transl Lung Cancer Res. 2014 Aug;3(4):212-24. doi: 10.3978/j.issn.2218-6751.2014.08.06. Transl Lung Cancer Res. 2014. PMID: 25806303 Free PMC article. Review.
Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy.
Guckenberger M, Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Ganswindt U, Hass P, Henkenberens C, Holy R, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Semrau S, Streblow J, Wendt TG, Wittig A, Flentje M, Sterzing F. Guckenberger M, et al. Among authors: andratschke n. Radiother Oncol. 2016 Mar;118(3):485-91. doi: 10.1016/j.radonc.2015.09.008. Epub 2015 Sep 15. Radiother Oncol. 2016. PMID: 26385265
Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases.
Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Flentje M, Ganswindt U, Hass P, Henkenberens C, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Schmitt V, Semrau S, Sterzing F, Streblow J, Wendt TG, Wittig A, Guckenberger M. Klement RJ, et al. Among authors: andratschke n. Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):841-9. doi: 10.1016/j.ijrobp.2015.12.004. Epub 2015 Dec 15. Int J Radiat Oncol Biol Phys. 2016. PMID: 26972657
Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, Blanck O, Wittig A, Boda-Heggemann J, Krempien R, Lohaus F, Klass ND, Eble MJ, Imhoff D, Kahl H, Petersen C, Gerum S, Henkenberens C, Adebahr S, Hass P, Schrade E, Wendt TG, Hildebrandt G, Andratschke N, Sterzing F, Guckenberger M. Rieber J, et al. Among authors: andratschke n. Lung Cancer. 2016 Jul;97:51-8. doi: 10.1016/j.lungcan.2016.04.012. Epub 2016 Apr 26. Lung Cancer. 2016. PMID: 27237028
Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease.
Rieber J, Abbassi-Senger N, Adebahr S, Andratschke N, Blanck O, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Lohr F, Petersen C, Schrade E, Streblow J, Uhlmann L, Wittig A, Sterzing F, Guckenberger M. Rieber J, et al. Among authors: andratschke n. Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):511-520. doi: 10.1016/j.ijrobp.2016.09.026. Epub 2016 Sep 26. Int J Radiat Oncol Biol Phys. 2017. PMID: 27843031
256 results